nortriptyline has been researched along with Deafness, Sudden in 1 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Deafness, Sudden: Complete sensorineural hearing loss which develops suddenly over a period of hours or a few days.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our hypothesis was that adjuvant migraine medications may improve outcomes in SSNHL." | 1.62 | Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss. ( Abouzari, M; Chua, JT; Djalilian, HR; Goshtasbi, K; Lin, HW; Saber, T; Sarna, B; Tan, D, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abouzari, M | 1 |
| Goshtasbi, K | 1 |
| Chua, JT | 1 |
| Tan, D | 1 |
| Sarna, B | 1 |
| Saber, T | 1 |
| Lin, HW | 1 |
| Djalilian, HR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss[NCT05403229] | Phase 2 | 140 participants (Anticipated) | Interventional | 2022-10-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for nortriptyline and Deafness, Sudden
| Article | Year |
|---|---|
Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss.
Topics: Administration, Oral; Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Glucocorticoids | 2021 |